PMID- 37771789 OWN - NLM STAT- Publisher LR - 20231003 IS - 2631-7745 (Electronic) IS - 2631-7745 (Linking) VI - 16 DP - 2023 Jan-Dec TI - Efficacy and safety of self-expanding metal stents in patients with inoperable esophageal cancer: a real-life study. PG - 26317745231200975 LID - 10.1177/26317745231200975 [doi] LID - 26317745231200975 AB - BACKGROUND: Dysphagia is the most frequent symptom in patients diagnosed with esophageal cancer. Self-expanding metal stents (SEMS) are the current palliative treatment of choice for dysphagia in patients with non-curable esophageal cancer. This study aimed to evaluate the efficacy and adverse events (AEs) of different types of SEMS for palliation of dysphagia. METHODS: We performed a retrospective cohort study of patients with advanced esophageal cancer and SEMS placement for dysphagia palliation in a tertiary care center. The primary outcome was the clinical success defined as an improvement in dysphagia (reduction of at least 2 points in the Mellow-Pinkas scoring system for dysphagia) after SEMS placement. RESULTS: Between January 1999 and May 2020, 295 patients with esophageal cancer were identified. Among them, 75 had a SEMS placement for dysphagia palliation. The mean age of the patients was 61.3 years (standard deviation: 13.4), 69 patients (92%) were men, and the mean Mellow-Pinkas scoring for dysphagia pre- and post-SEMS placement were 3.1 and 1.4 (change from baseline -1.7), respectively. Technical success and clinical success were achieved in 98.6% and 58.9%, respectively. AEs were identified in 35/75 patients (46.7%), and SEMS migration was the most frequent AE in 22/75 patients (29.3%). There were no significant differences in improvement in dysphagia (p = 0.054), weight changes (p = 0.78), and AE (p = 0.73) among fully covered SEMS (fc-SEMS) and partially covered SEMS (pc-SEMS). The median follow-up was 89 days (interquartile range: 29-221). CONCLUSION: SEMS placement was associated with a rapid improvement in dysphagia, high technical success, and a modest improvement in dysphagia with no major AE among fc-SEMS and pc-SEMS. CI - (c) The Author(s), 2023. FAU - Jimenez-Gutierrez, Jose Miguel AU - Jimenez-Gutierrez JM AUID- ORCID: 0000-0003-3157-4480 AD - Department of Endoscopy, Instituto Nacional de Cancerologia, San Fernando 22, Tlalpan, Ciudad de Mexico 14080, Mexico. FAU - Alonso-Larraga, Juan Octavio AU - Alonso-Larraga JO AD - Department of Endoscopy, Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico. FAU - Hernandez-Guerrero, Angelica I AU - Hernandez-Guerrero AI AD - Department of Endoscopy, Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico. FAU - Lino-Silva, Leonardo Saul AU - Lino-Silva LS AUID- ORCID: 0000-0002-7394-5123 AD - Department of Surgical Pathology, Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico. FAU - Olivas-Martinez, Antonio AU - Olivas-Martinez A AD - Department of Biostatistics, University of Washington, Seattle, WA, USA. LA - eng PT - Journal Article DEP - 20230926 PL - United States TA - Ther Adv Gastrointest Endosc JT - Therapeutic advances in gastrointestinal endoscopy JID - 101741179 PMC - PMC10524049 OTO - NOTNLM OT - dysphagia OT - esophageal cancer OT - self-expanding metal stents COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/09/29 06:43 MHDA- 2023/09/29 06:43 PMCR- 2023/09/26 CRDT- 2023/09/29 03:56 PHST- 2023/03/01 00:00 [received] PHST- 2023/08/28 00:00 [accepted] PHST- 2023/09/29 06:43 [medline] PHST- 2023/09/29 06:43 [pubmed] PHST- 2023/09/29 03:56 [entrez] PHST- 2023/09/26 00:00 [pmc-release] AID - 10.1177_26317745231200975 [pii] AID - 10.1177/26317745231200975 [doi] PST - epublish SO - Ther Adv Gastrointest Endosc. 2023 Sep 26;16:26317745231200975. doi: 10.1177/26317745231200975. eCollection 2023 Jan-Dec.